TICKERNOMICS Sign up
Last Update: 2024-12-27 15:25:32
Annexon Inc. ( ANNX ) https://www.annexonbio.com
5.26USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
ANNX
15.10%
SPY
32.66%
-56.31%
ANNX
SPY
108.59%
ANNX
0.00%
SPY
302.52%
ANNX
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
738.85
428.34
0.55
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-6.29
151.84
2.23
-12.74
0.00
-3.08
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-587.18
-17.39
-713.55
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.32
-67.41
-52.00
0.00
Other Earnings and Cash Flow Stats:
Annexon Inc. ( ANNX ) Net Income TTM ($MM) is -117.50
Annexon Inc. ( ANNX ) Operating Income TTM ($MM) is -131.60
Annexon Inc. ( ANNX ) Owners' Earnings Annual ($MM) is 0.00
Annexon Inc. ( ANNX ) Current Price to Owners' Earnings ratio is 0.00
Annexon Inc. ( ANNX ) EBITDA TTM ($MM) is -129.45
Annexon Inc. ( ANNX ) EBITDA Margin is -713.55%
Capital Allocation:
Annexon Inc. ( ANNX ) has paid 0.00 dividends per share and bought back -64.590524 million shares in the past 12 months
Annexon Inc. ( ANNX ) has reduced its debt by 1.901 million USD in the last 12 months
Capital Structure:
Annexon Inc. ( ANNX ) Interest-bearing Debt ($MM) as of last quarter is 29
Annexon Inc. ( ANNX ) Annual Working Capital Investments ($MM) are -64
Annexon Inc. ( ANNX ) Book Value ($MM) as of last quarter is 331
Annexon Inc. ( ANNX ) Debt/Capital as of last quarter is 8%
Other Balance Sheet Stats:
Annexon Inc. ( ANNX ) has 79 million in cash on hand as of last quarter
Annexon Inc. ( ANNX ) has 20 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Annexon Inc. ( ANNX ) has 139 common shares outstanding as of last quarter
Annexon Inc. ( ANNX ) has 0 million USD of preferred stock value
Academic Scores:
Annexon Inc. ( ANNX ) Altman Z-Score is 6.79 as of last quarter
Annexon Inc. ( ANNX ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
Annexon Inc. ( ANNX ) largest shareholder is owning shares at 0.00 ($MM) value
Carson William H.(an insider) Bought 3200 shares of Annexon Inc. ( ANNX ) for the amount of $17056.00 on 2024-12-02
0.50% of Annexon Inc. ( ANNX ) is held by insiders, and 106.10% is held by institutions
Annexon Inc. ( ANNX ) went public on 2020-07-24
Other Annexon Inc. ( ANNX ) financial metrics:
FCF:-105.49
Unlevered Free Cash Flow:0.00
EPS:-1.00
Operating Margin:-587.18
Gross Profit Margin:-17.39
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-42.01
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Annexon Inc. ( ANNX ) :
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.